Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-2-23
pubmed:abstractText
The aim of this study was to define the recommended dose of oxaliplatin when combined with infusional 5-fluorouracil (5-FU) and concurrent pelvic radiotherapy. Eligible patients had inoperable rectal cancer, or symptomatic primary rectal cancer with metastasis. Oxaliplatin was given on day 1 of weeks 1, 3 and 5 of radiotherapy. Dose level 1 was oxaliplatin 70 mg m(-2) with 5-FU 200 mg m(-2) day(-1) continuous infusion 96 h week(-1). On dose level 2, the oxaliplatin dose was increased to 85 mg m(-2). On dose level 3, the duration of the 5-FU was increased to 168 h per week. Pelvic radiotherapy was 45 Gray (Gy) in 25 fractions over 5 weeks with a boost of 5.4 Gy. Fluorine-18 fluoro deoxyglucose and Fluorine-18 fluoro misonidazole positron emission tomography (FDG-PET and FMISO-PET) were used to assess metabolic tumour response and hypoxia. In all, 16 patients were accrued. Dose-limiting toxicities occurred in one patient at level 2 (grade 3 chest infection), and two patients at level 3 (grade 3 diarrhoea). Dose level 2 was declared the recommended dose level. FDG-PET imaging showed metabolic responses in 11 of the 12 primary tumours assessed. Four of six tumours had detectable hypoxia on FMISO-PET scans. The addition of oxaliplatin to infusional 5-FU chemoradiotherapy was feasible and generally well tolerated. For future trials, oxaliplatin 85 mg m(-2) and 5-FU 200 mg m(-2) day(-1) continuous infusion 96 h week(-1) is the recommended dose when combined with 50.4 Gy of pelvic radiotherapy.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-10421535, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-10561302, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-10673991, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-10944126, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-10944647, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-11134203, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-11331322, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-12243813, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-12416580, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-12663716, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-12915600, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-14665611, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-15496622, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-1997835, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-2405793, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-6534106, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-8041415, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-8079744, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-8133857, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-8661826, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-8961365, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-9091798, http://linkedlifedata.com/resource/pubmed/commentcorrection/15700033-9278661
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:day
28
pubmed:volume
92
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
655-61
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:15700033-Adult, pubmed-meshheading:15700033-Aged, pubmed-meshheading:15700033-Aged, 80 and over, pubmed-meshheading:15700033-Antimetabolites, Antineoplastic, pubmed-meshheading:15700033-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15700033-Chemotherapy, Adjuvant, pubmed-meshheading:15700033-Drug Administration Schedule, pubmed-meshheading:15700033-Female, pubmed-meshheading:15700033-Fluorodeoxyglucose F18, pubmed-meshheading:15700033-Fluorouracil, pubmed-meshheading:15700033-Humans, pubmed-meshheading:15700033-Infusions, Intravenous, pubmed-meshheading:15700033-Male, pubmed-meshheading:15700033-Middle Aged, pubmed-meshheading:15700033-Misonidazole, pubmed-meshheading:15700033-Neoplasm Staging, pubmed-meshheading:15700033-Organoplatinum Compounds, pubmed-meshheading:15700033-Positron-Emission Tomography, pubmed-meshheading:15700033-Radiopharmaceuticals, pubmed-meshheading:15700033-Radiotherapy, Adjuvant, pubmed-meshheading:15700033-Radiotherapy Dosage, pubmed-meshheading:15700033-Rectal Neoplasms, pubmed-meshheading:15700033-Treatment Outcome
pubmed:year
2005
pubmed:articleTitle
Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial.
pubmed:affiliation
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, A'Beckett Street, Melbourne, Victoria 8006, Australia.
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase I